Our top pick for
Hanger Inc is a medical care facilities business based in the US. Hanger shares (HNGR) are listed on the NYSE and all prices are listed in US Dollars. Hanger employs 4,700 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$18.53|
|52-week range||$17.10 - $26.68|
|50-day moving average||$20.98|
|200-day moving average||$23.56|
|Wall St. target price||$29.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.76|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-22)||N/A|
|3 months (2021-07-26)||-23.27%|
|6 months (2021-04-26)||-23.02%|
|1 year (2020-10-26)||-0.91%|
|2 years (2019-10-25)||-14.84%|
|3 years (2018-10-26)||18.63|
|5 years (2016-10-26)||133.96%|
Valuing Hanger stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hanger's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hanger's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Hanger shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hanger's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.71. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hanger's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hanger's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $97.4 million.
The EBITDA is a measure of a Hanger's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.1 billion|
|Operating margin TTM||6.11%|
|Gross profit TTM||$333.9 million|
|Return on assets TTM||4.32%|
|Return on equity TTM||70.13%|
|Market capitalisation||$716.5 million|
TTM: trailing 12 months
There are currently 1.1 million Hanger shares held short by investors – that's known as Hanger's "short interest". This figure is 9.2% up from 965,505 last month.
There are a few different ways that this level of interest in shorting Hanger shares can be evaluated.
Hanger's "short interest ratio" (SIR) is the quantity of Hanger shares currently shorted divided by the average quantity of Hanger shares traded daily (recently around 152997.09724238). Hanger's SIR currently stands at 6.89. In other words for every 100,000 Hanger shares traded daily on the market, roughly 6890 shares are currently held short.
However Hanger's short interest can also be evaluated against the total number of Hanger shares, or, against the total number of tradable Hanger shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hanger's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Hanger shares in existence, roughly 30 shares are currently held short) or 0.0456% of the tradable shares (for every 100,000 tradable Hanger shares, roughly 46 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Hanger.
Find out more about how you can short Hanger stock.
We're not expecting Hanger to pay a dividend over the next 12 months.
Hanger's shares were split on a 1:4 basis on 30 December 1990. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hanger shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Hanger shares which in turn could have impacted Hanger's share price.
Over the last 12 months, Hanger's shares have ranged in value from as little as $17.1 up to $26.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Hanger's is 1.5471. This would suggest that Hanger's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Hanger, Inc. provides orthotic and prosthetic (O&P) services; and distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings in the United States. It operates through two segments, Patient Care and Products & Services. The Patient Care segment owns and operates Hanger clinic, which specializes in the design, fabrication, and delivery of custom O&P devices through patient care clinics and satellite locations; and provides payor network contracting services to other O&P providers. The Products & Services segment distributes O&P parts, componentry, and devices to independent O&P providers; and develops specialized rehabilitation technologies and provides evidence-based clinical programs for post-acute rehabilitation to patients at approximately 4,000 skilled nursing and post-acute providers. This segment also manufactures and sells therapeutic footwear for diabetic patients in the podiatric market. As of December 31, 2020, the company operated approximately 704 patient care clinics, and 112 satellite locations in 46 states and the District of Columbia.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.